Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biorem's revenue for the
three
months ended in Mar. 2026 was $4.97 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $32.28 Mil.
Biorem's Revenue per Share for the
three
months ended in Mar. 2026 was $0.27.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.74.
During the past 12 months, the average Revenue per Share Growth Rate of Biorem was 23.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 11.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 32.20% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 18.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Biorem's highest 3-Year average Revenue per Share Growth Rate was 440.40% per year. The lowest was -66.40% per year. And the median was 4.05% per year.
Biorem (OTCPK:BIRMF) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Biorem Revenue Related Terms
Biorem Revenue Historical Data
* Premium members only.
The historical data trend for Biorem's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pollution & Treatment Controls subindustry, Biorem's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biorem Revenue vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Biorem's Revenue distribution charts can be found below:
* The bar in red indicates where Biorem's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $32.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biorem (BIRMF) has a Revenue of $32.28 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Biorem and its competitors.
Is Biorem's Revenue too high?
Biorem's current Revenue is $32.28 Mil. Overall, Biorem has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biorem's Revenue compare to VLTO and ZWS?
Biorem's Revenue of $32.28 Mil can be compared against companies in the Industrial Products industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for an Industrial Products company?
A good Revenue depends on the Industrial Products industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Biorem and its competitors. Biorem's current Revenue is $32.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biorem stock overvalued right now?
Based on GuruFocus' analysis, Biorem (BIRMF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.94, compared to a current price of $2.17 — trading 11.9% above its estimated fair value. The current Revenue is $32.28 Mil. Biorem's overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Biorem (BIRMF), the current Revenue is $32.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biorem (BIRMF) Overvalued in 2026?
Based on GuruFocus' analysis, Biorem stock appears to be overvalued.
The current stock price of $2.17 is trading 11.9% above its estimated GF Value™ of $1.94.
GuruFocus considers Biorem to be Modestly Overvalued.
Key valuation signals for BIRMF:
Revenue: $32.28 Mil
GF Value™: $1.94 vs. price of $2.17 (11.9% above fair value)
No single metric tells the full story. See the BIRMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biorem Inc is an environmental biotechnology company. It is involved in the manufacturing of a comprehensive line of high efficiency air pollution control systems that are used to eliminate odorous and harmful contaminants. The company's products include Biofilters, Biogas Solutions, Multi-Stage Systems, Biotrickling filters, and services such as Media Sampling and Analysis, Biological processes and testing, Media replacements and Spare parts, and other related services. The company derives revenues from the sale of standard products, construction projects for specialized products, and services for repairs and maintenance. The group has a business presence in Canada, the United States, China and others, of which key revenue is derived from the United States.
88GF Score
Get the complete analysis for BIRMF
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIRMF has been successfully added to your 
